• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology. It focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. The company?s marketed products include ZEVALIN, a prescribed form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. Its late stage development products comprise apaziquone for the treatment of non-muscle invasive bladder cancer; and Belinostat, a histone deacytelase inhibitor for the treatment of various hematological and solid tumors. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

NO
     
SPPI (Spectrum Pharmaceuticals Inc)
Last Trade 2.83 Date 2/15/2020
Change % -0.36 % Price Change -0.01
Open 2.83 52 Week High 12.15
High 2.87 52 Week Low 2.48
Low 2.74 Type stock
Volume 1070075 Average Volume 2587197
Prev Close 2.84 Stock Exchange NASDAQ
Bid 2.75 Ask 2.98
Bid Size 1 Ask Size 2
1st Yr Estimated EPS Growth 0.0154 2nd Yr Estimated EPS Growth -0.4621
2 Years Forward Earning Yield -0.2509 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 2.0777 Book Value Yield 0.7342
Buy Back Yield CAPE Ratio
Cash Return -1.6792 Cash Flow per Share -1.061
Cash Flow Yield -0.3749 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.4594 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 25.2358 EV / Pre Tax Income
EV / Revenue 0.6924 EV / Total Asset 0.2577
Expected Dividend Growth Rate Free Cash Flow per Share -1.1653
Free Caash Flow Ratio Free Cash Flow Yield -0.4118
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.4664 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.362116 PB Ratio 10 Year Growth -0.037942
PB Ratio 3 Year Growth 4.460259 Cash Ratio 3 Year Average 572.5553
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 34.686909 PE Ratio 10 Year Growth
PE Ratio 10 Year High 259.0 PE Ratio 10 Year Low 4.794521
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.118577
Price to Cash Ratio 1.290409 Price / EBITDA
Price to Sales Ratio 2.823848 Price to Sales Ratio 10 Year Growth -0.04733
Price to Sales Ratio 3 Year Avg 9.124471 Price to Sales Ratio 5 Year Avg
Sale per Share 1.0022 Sales Yield 0.3541
Sustainable Growth Rate -0.4708 Tangible Book Value per Share 2.0777
Tangible Book Value per Share 3 year Avg 1.624 Tangible Book Value per Share 5 year Avg 1.1133
Total Asset per Share 2.6008 Total Yield
Working Capital per Share 1.9909 Working Capital per Share 3 Year Avg 1.9701
Working Capital per Share 5 Year Avg 1.9166 Beta 3.061861